Navigation Links
ESAI provides grant to LA BioMed to investigate long-term correction of erectile dysfunction
Date:10/5/2009

LOS ANGELES (Oct. 5, 2009) Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) announced today that it will award a $1.3 million grant to Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) for pre-clinical studies aimed at activating penile endogenous (adult) stem cells with the company's drug, KRONOS IV. ESAI's ultimate goal is the use of the drug to provide long-term correction of male erectile dysfunction in an aged population, as well as in patients with diabetes and those who have undergone prostatectomy for prostate cancer.

ESAI and LA BioMed signed a research contract in which Nestor Gonzalez-Cadavid, PhD, the principal investigator for the proposed research at LA BioMed, will lead the institute's research team. Dr. Gonzalez-Cadavid will be using technology he has applied successfully before that led to the restoration of erectile function and the generation of new cells in the penile tissues of animal models after the implantation of adult stem cells derived from skeletal muscles. The repair of penile tissue was a result of the generation of new smooth muscle cells that replaced the ones lost during the aging process.

"We appreciate ESAI's vote of confidence in LA BioMed and our research capabilities," said Dr. Gonzalez-Cadavid. "While the use of adult stem cells derived from skeletal muscles in our previous research is a novel and promising approach, its application in the clinic is still remote because it is invasive, restricted to the donor patient, expensive to generate and difficult to achieve approval under the Food and Drug Administration's (FDA) regulations. KRONOS IV is based upon a generic drug presently on the market and approved by the FDA in the treatment of a certain medical condition, making it more available and less expensive."

Alfred T. Sapse, MD(r), ESAI's president, said the ESAI technology has "transformed this generic drug by using proprietary techniques including novel ways of manufacturing it into a potentially effective activator of endogenous stem cells into certain desired cell lineages for tissue repair without changing the generic drug's formulation."

The research contract between ESAI and LA BioMed calls for basic and pre-clinical research on the drug over three years.

"ESAI assumes, based upon preliminary results, that a positive pre-clinical outcome for erectile dysfunction with the KRONOS IV compounds could be obtained in as few as 12 months," said Dr. Sapse. "If that occurs, ESAI then plans to proceed with clinical studies as carried out previously with other off-label drugs in three groups of ten patients each. If successful, this would enable physicians to prescribe KRONOS IV as an off-label drug in the treatment of erectile dysfunction."

Sapse said ESAI also intends to continue to collaborate with LABioMed within the current contract with pre-clinical testing and basic research to provide the answers on how KRONOS IV works locally on the regeneration of the smooth muscle, nerve terminals and various other types of cells in the penile corpora cavernosa, or erectile tissue. In addition, the research will seek to identify both the specific cellular targets for this action and any potential systemic effects throughout the body.


'/>"/>

Contact: Laura Mecoy
lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... 27, 2017 , ... Atmosera , a premier Microsoft ... Services . The trusted, transparent, and secure solution for the cloud enablement of ... Atmosera’s next generation services include integrated capabilities for public, private, and hybrid Azure ...
(Date:6/27/2017)... ... 2017 , ... Today, June 27th is PTSD Awareness Day. Over half a ... receive adequate care due to lack of effective treatments, fear of stigma or insufficient ... left untreated, veterans are at an increased risk for self-destructive behavior, including alcohol/drug abuse, ...
(Date:6/26/2017)... ... 2017 , ... Torrance dentist, Dr. Robert Mondavi DDS , is now ... aspects of a person’s appearance. A healthy, radiant smile can make a person look ... everyone can have the smile of their dreams with cosmetic dentistry. , “The field ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... ... according to a recent review of government data released by the United Soybean ... in management practices, Maryland’s soybean farmers have increased their productivity on less land ...
(Date:6/26/2017)... , ... June 26, 2017 , ... KICKICO , ... whitepaper that pledges to solve many catastrophic issues within funding campaigns. KICKICO developers ... The typical notion of crowdfunding - the raising of funds through the power of ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away with ... platform is described by Forbes as "entering the life ... Medical Association as teaching "empathy to medical professionals in ... startup was recently named a finalist for the Department ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
Breaking Medicine Technology: